Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses
Open accessThe DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
Background: Clozapine remains the only evidence-based antipsychotic for treatment-resistant schizophrenia (TRS). The ability to predict which patients with their first onset of schizophrenia would subsequently meet criteria for treatment resistance (TR) could help to diminish the severe functional disability which may ensue if TR is not recognized and correctly treated. Method: This is a 5-year longitudinal assessment of clinical outcomes in a cohort of 246 first-episode schizophrenia spectrum patients recruited as part of the NIHR Genetics and Psychosis (GAP) study conducted in South London from 2005 to 2010. We examined the relationship between baseline demographic and clinical measures and the emergence of TR. TR status was determined from a review of electronic case records. We assessed for associations with early-, and late-onset TR, and non-TR, and differences between those TR patients treated with clozapine and those who were not. Results: Seventy per cent ( n = 56) of TR patients, and 23% of the total study population ( n = 246) were treatment resistant from illness onset. Those who met criteria for TR during the first 5 years of illness were more likely to have an early age of first contact for psychosis (<20 years) [odds ratio (OR) 2.49, 95% confidence interval (CI) 1.25–4.94] compared to those with non-TR. The relationship between an early age of first contact (<20 years) and TR was significant in patients of Black ethnicity (OR 3.71, 95% CI 1.44–9.56); and patients of male gender (OR 3.13 95% CI 1.35–7.23). Conclusions: For the majority of the TR group, antipsychotic TR is present from illness onset, necessitating increased consideration for the earlier use of clozapine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Prevalence estimates of TRS, TRD, and treatment resistant OCD vary from 20-60% of the population with the condition. 26, 35–40”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [26]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378 · cited 1×
“The degree of psychopathology at first presentation to mental health services was measured on the Positive and Negative Syndrome Scale (PANSS; Kay et al. 1987).”
MethodA solution to the problem of separation in logistic regression
Heinze, G., & Schemper, M. (2002) · Statistics in Medicine · doi:10.1002/sim.1047 · Cited by 2,711 · cited 1×
“Penalized logistic regression (PLR) was used to analyse the relationship between the predictors for TR (Heinze & Schemper, 2002).”
MethodRemission in Schizophrenia: Proposed Criteria and Rationale for Consensus
Andreasen, N. C., Carpenter, W. T., Kane, J. M., Lasser, R. A., Marder, S. R., & Weinberger, D. R. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.3.441 · Cited by 2,343 · cited 1×
“…for TR. Similar to earlier work conducted in the same geographical region (Morgan et al. 2014; Revier et al. 2015), and in keeping with work from Andreasen et al. (2005), using information extracted from clinical records, remission was defined as the absence of overt psychotic symptoms,…”
ResultMcGuffin, P. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810320088015 · Cited by 1,483 · cited 2×
“The OPCRIT system consists of a 90-item checklist and uses computerized diagnostic algorithms based on published criteria to provide a diagnostic category for each subject employing a number of classification systems (McGuffin et al. 1991).”
MethodNatural Course of Schizophrenic Disorders: A 15-Year Followup of a Dutch Incidence Cohort
Wiersma, D., Nienhuis, F. J., Slooff, C. J., & Giel, R. (1998) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033315 · Cited by 649 · cited 3×
“This finding mirrors the rate of 20% who displayed ‘chronicity’ from illness outset in a FEP population (Wiersma et al. 1998), although is higher than a previous finding of 10% of FEP cases found to have shown no response to antipsychotics at the end of the first year of treatment (Robinson et al.…”
BackgroundResultHigh-potency cannabis and the risk of psychosis
Di Forti, M., Morgan, C., Dazzan, P., Pariante, C., Mondelli, V., Marques, T. R., Handley, R., Luzi, S., Russo, M., Paparelli, A., et al. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.064220 · Cited by 567 · cited 1×
“A detailed assessment of lifetime patterns of cannabis use and alcohol intake was collated employing the Cannabis Experience Questionnaire modified version (Di Forti et al. 2009).”
MethodSelf-citationTreatment-Resistant Schizophrenia - The Role of Clozapine
Meltzer, H. Y. (1997) · Current Medical Research and Opinion · doi:10.1185/03007999709113338 · Cited by 491 · cited 3×
“Although, a few potential risk factors for TR, such as poor premorbid functioning, living in less urban areas, co-morbid personality disorder, longer duration of untreated psychosis (DUP), greater severity of negative symptoms, and a younger age of illness onset have been suggested (Vanelle et al. 1994; Meltzer, 1997;…”
BackgroundDi Forti, M., Sallis, H., Allegri, F., Trotta, A., Ferraro, L., Stilo, S. A., Marconi, A., La Cascia, C., Reis Marques, T., Pariante, C., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt181 · Cited by 470 · cited 1×
“Further details of the study are available in Di Forti et al. (2014).”
BackgroundSelf-citationPredictors of Treatment Response From a First Episode of Schizophrenia or Schizoaffective Disorder
Robinson, D. G., Woerner, M. G., Alvir, J. M. J., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., Bilder, R., Goldman, R., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.4.544 · Cited by 466 · cited 2×
“1998), although is higher than a previous finding of 10% of FEP cases found to have shown no response to antipsychotics at the end of the first year of treatment (Robinson et al. 1999).”
ResultWechsler Adult Intelligence Scale
Szczepkowski, K. V., & Demakis, G. J. (2017) · Encyclopedia of Personality and Individual Differences · doi:10.1007/978-3-319-28099-8_1034-1 · Cited by 440
Lewis, S. W., Barnes, T. R. E., Davies, L., Murray, R. M., Dunn, G., Hayhurst, K. P., Markwick, A., Lloyd, H., & Jones, P. B. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj067 · Cited by 422 · cited 1×
“Early identification of patients who require clozapine has the potential to improve clinical outcomes and minimize the social and functional disability that results from prolonged psychosis (Lewis et al. 2006; Wheeler et al. 2009; Stroup et al. 2016).”
BackgroundSelf-citationDose Equivalents for Second-Generation Antipsychotics: The Minimum Effective Dose Method
Leucht, S., Samara, M., Heres, S., Patel, M. X., Woods, S. W., & Davis, J. M. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu001 · Cited by 372 · cited 1×
“An adequate daily dose of antipsychotic medication was defined according to a daily dose of at least 400 mg chlorpromazine equivalence (Leucht et al. 2014).”
BackgroundHowes, O. D., Vergunst, F., Gee, S., McGuire, P., Kapur, S., & Taylor, D. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.105833 · Cited by 353 · cited 3×
“…of early resistance of those with TR in this population is an important finding, which needs to be viewed in relation to the delay in clozapine use which exists in clinical practice (Howes et al. 2012), specifically the under use of clozapine within the first 1–2 years of illness presentation.”
BackgroundInfluentialSelf-citationDemjaha, A., Egerton, A., Murray, R. M., Kapur, S., Howes, O. D., Stone, J. M., & McGuire, P. K. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.06.011 · Cited by 342 · cited 1×
“…course of illness is not associated with prior antipsychotic use and raises the possibility that it may be a distinctive and homogenous schizophrenia subgroup, in line with evidence that there are biological differences between TR and treatment-responsive schizophrenia (Demjaha et al. 2012, 2014).”
ResultSelf-citationA systematic review of longitudinal outcome studies of first-episode psychosis
MENEZES, N. M., ARENOVICH, T., & ZIPURSKY, R. B. (2006) · Psychological Medicine · doi:10.1017/s0033291706007951 · Cited by 333 · cited 1×
“Further, while there is a large literature investigating predictors of treatment response and remission from illness onset (Menezes et al. 2006; Carbon & Correll, 2014), TR has not been examined longitudinally as an outcome measure in first-episode psychosis (FEP).”
BackgroundDopamine Synthesis Capacity in Patients With Treatment-Resistant Schizophrenia
Demjaha, A., Murray, R. M., McGuire, P. K., Kapur, S., & Howes, O. D. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12010144 · Cited by 325 · cited 1×
“…course of illness is not associated with prior antipsychotic use and raises the possibility that it may be a distinctive and homogenous schizophrenia subgroup, in line with evidence that there are biological differences between TR and treatment-responsive schizophrenia (Demjaha et al. 2012, 2014).”
ResultSelf-citationClinical predictors of therapeutic response to antipsychotics in schizophrenia
Carbon, M., & Correll, C. U. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.4/mcarbon · Cited by 257
Determining the chronology and components of psychosis onset: The Nottingham Onset Schedule (NOS)
Singh, S. P., Cooper, J. E., Fisher, H. L., Tarrant, C. J., Lloyd, T., Banjo, J., Corfe, S., & Jones, P. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.04.018 · Cited by 252 · cited 1×
“DUP was defined as the difference between the date of onset of psychotic symptoms to the date of treatment with antipsychotic medications (Singh et al. 2005; Malla et al. 2006).”
BackgroundReappraising the long-term course and outcome of psychotic disorders: the AESOP-10 study
Morgan, C., Lappin, J., Heslin, M., Donoghue, K., Lomas, B., Reininghaus, U., Onyejiaka, A., Croudace, T., Jones, P. B., Murray, R. M., et al. (2014) · Psychological Medicine · doi:10.1017/s0033291714000282 · Cited by 248
Self-citationWechsler Test of Adult Reading
Hill, A. K., Venegas, J., & Clark, E. (2017) · Encyclopedia of Clinical Neuropsychology · doi:10.1007/978-3-319-56782-2_1500-2 · Cited by 246
Agid, O., Arenovich, T., Sajeev, G., Zipursky, R. B., Kapur, S., Foussias, G., & Remington, G. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05785yel · Cited by 224 · cited 2×
“study, 70% of those with TR would have been most appropriately treated with clozapine at an early stage of their presentation, particularly given evidence that early treatment with clozapine is effective (Agid et al., 2011), and that worse outcomes are seen with a delayed use of clozapine(Nielsen et al.”
BackgroundPredictors of rate and time to remission in first-episode psychosis: a two-year outcome study
MALLA, A., NORMAN, R., SCHMITZ, N., MANCHANDA, R., BÉCHARD-EVANS, L., TAKHAR, J., & HARICHARAN, R. (2006) · Psychological Medicine · doi:10.1017/s0033291706007379 · Cited by 217 · cited 2×
“symptoms to the date of treatment with antipsychotic medications (Singh et al. 2005; Malla et al. 2006).”
BackgroundSartorius, N., Gulbinat, W., Harrison, G., Laska, E., & Siegel, C. (1996) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/bf00787917 · Cited by 208 · cited 1×
“At follow-up, extensive information was collated across clinical and social outcome domains, from clinical records using the WHO Life Chart Schedule (LCS) extended version (Sartorius et al. 1996).”
MethodKolakowska, T., Williams, A. O., Ardern, M., Reveley, M. A., Jambor, K., Gelder, M. G., & Mandelbrote, B. M. (1985) · British Journal of Psychiatry · doi:10.1192/bjp.146.3.229 · Cited by 194 · cited 2×
“Further, our finding that 70% of the TR group displayed E-TR, is similar to an earlier study in established schizophrenia, which identified that over half of patients with ‘poor outcomes’, remained psychotic from illness onset (Kolakowska et al. 1985).”
BackgroundResultAge at onset and gender of schizophrenic patients in relation to neuroleptic resistance
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.475 · Cited by 184 · cited 1×
“TR (Vanelle, 1995; Meltzer et al. 1997), although our study is the first longitudinal study in first-episode schizophrenia spectrum psychoses to identify this.”
ResultStroup, T. S., Gerhard, T., Crystal, S., Huang, C., & Olfson, M. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15030332 · Cited by 173
Chouinard, G., & Chouinard, V.-A. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000112883 · Cited by 168 · cited 1×
“Dopamine supersensitivity is postulated to occur due to up-regulation of dopamine receptors and neural adaptation (Chouinard, 1991; Iyo et al. 2013) and it has been estimated that 50% of TR might be due to the emergence of dopamine supersensitivity (Chouinard & Chouinard, 2008).”
BackgroundPredictors of treatment resistance in patients with schizophrenia: a population-based cohort study
Wimberley, T., Støvring, H., Sørensen, H. J., Horsdal, H. T., MacCabe, J. H., & Gasse, C. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00575-1 · Cited by 153 · cited 1×
“…onset have been suggested (Vanelle et al. 1994; Meltzer, 1997; Schennach et al. 2012; Ortiz et al. 2013; Frank et al. 2015; Martin & Mowry, 2016; Wimberley et al. 2016), the predictive value of specific clinical and demographic factors on TR in first-episode schizophrenia has not yet been…”
BackgroundSelf-citationSocial environment, ethnicity and schizophrenia: A case-control study
Mallett, R., Leff, J., Bhugra, D., Pang, D., & Zhao, J. H. (2002) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-002-0557-4 · Cited by 151 · cited 2×
“Information on sociodemographic characteristics was collated using the Medical Research Council (MRC) Socio-demographic Schedule modified version (Mallett et al. 2002).”
MethodEarly-onset schizophrenia: A 15-year follow-up
Röpcke, B., & Eggers, C. (2005) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-005-0483-6 · Cited by 140 · cited 1×
“Early-onset schizophrenia is associated with worse outcomes compared to adult-onset schizophrenia (Ropcke & Eggers, 2005; Vyas et al. 2007), and a younger age of illness onset has been previously associated with the emergence of T ab le 3.”
BackgroundGeographic and Clinical Variation in Clozapine Use in the United States
Stroup, T. S., Gerhard, T., Crystal, S., Huang, C., & Olfson, M. (2013) · Psychiatric Services · doi:10.1176/appi.ps.201300180 · Cited by 135 · cited 1×
“…investigating risk factors for treatment resistance (TR) have utilized clozapine prescription rates as a proxy measure of TR (Nielsen et al. 2012b; Stroup et al. 2014; Schneider et al. 2015); however, given the under-utilization of clozapine in clinical practice, such studies do not measure all…”
BackgroundTen-Year Outcomes of First-Episode Psychoses in the MRC ÆSOP-10 Study
Revier, C. J., Reininghaus, U., Dutta, R., Fearon, P., Murray, R. M., Doody, G. A., Croudace, T. J., Dazzan, P., Heslin, M., Onyejiaka, A. N., et al. (2015) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000000295 · Cited by 130 · cited 1×
“…of nonclozapine antipsychotics, meeting the criteria for TR. Similar to earlier work conducted in the same geographical region (Morgan et al. 2014; Revier et al. 2015), and in keeping with work from Andreasen et al. (2005), using information extracted from clinical records, remission was defined…”
ResultSelf-citationIdentification of increased genetic risk scores for schizophrenia in treatment-resistant patients
Frank, J., Lang, M., Witt, S. H., Strohmaier, J., Rujescu, D., Cichon, S., Degenhardt, F., Nöthen, M. M., Collier, D. A., Ripke, S., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.56 · Cited by 126 · cited 2×
“Although, a few potential risk factors for TR, such as poor premorbid functioning, living in less urban areas, co-morbid personality disorder, longer duration of untreated psychosis (DUP), greater severity of negative symptoms, and a younger age of illness onset have been suggested (Vanelle et al. 1994; Meltzer, 1997;…”
Severe cases of neuroleptic-induced supersensitivity psychosis
Chouinard, G. (1991) · Schizophrenia Research · doi:10.1016/0920-9964(91)90050-2 · Cited by 123 · cited 1×
“Dopamine supersensitivity is postulated to occur due to up-regulation of dopamine receptors and neural adaptation (Chouinard, 1991; Iyo et al. 2013) and it has been estimated that 50% of TR might be due to the emergence of dopamine supersensitivity (Chouinard & Chouinard, 2008).”
BackgroundDelayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia
Üçok, A., Çıkrıkçılı, U., Karabulut, S., Salaj, A., Öztürk, M., Tabak, Ö., & Durak, R. T. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000086 · Cited by 116 · cited 1×
“…have been most appropriately treated with clozapine at an early stage of their presentation, particularly given evidence that early treatment with clozapine is effective (Agid et al. 2011), and that worse outcomes are seen with a delayed use of clozapine (Nielsen et al. 2012a, Ucok et al. 2015).”
BackgroundTreatment response after relapse in a placebo-controlled maintenance trial in schizophrenia
Emsley, R., Nuamah, I., Hough, D., & Gopal, S. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.02.030 · Cited by 110 · cited 1×
“,(Emsley et al., 2012) in which patients had a treatment initiation at the time of relapse.”
BackgroundIyo, M., Tadokoro, S., Kanahara, N., Hashimoto, T., Niitsu, T., Watanabe, H., & Hashimoto, K. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31828ea95c · Cited by 105 · cited 1×
“Dopamine supersensitivity is postulated to occur due to up-regulation of dopamine receptors and neural adaptation (Chouinard, 1991; Iyo et al. 2013) and it has been estimated that 50% of TR might be due to the emergence of dopamine supersensitivity (Chouinard & Chouinard, 2008).”
BackgroundGeographical and temporal variations in clozapine prescription for schizophrenia
Nielsen, J., Røge, R., Schjerning, O., Sørensen, H. J., & Taylor, D. M. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.03.003 · Cited by 102 · cited 3×
“Previous studies investigating risk factors for treatment resistance (TR) have utilized clozapine prescription rates as a proxy measure of TR (Nielsen et al. 2012b; Stroup et al. 2014; Schneider et al. 2015); however, given the under-utilization of clozapine in clinical practice, such studies do not measure all people…”
BackgroundPredictors of Clozapine Response in Patients With Treatment-Refractory Schizophrenia
Nielsen, J., Nielsen, R. E., & Correll, C. U. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318267b3cd · Cited by 98 · cited 2×
“…have been most appropriately treated with clozapine at an early stage of their presentation, particularly given evidence that early treatment with clozapine is effective (Agid et al. 2011), and that worse outcomes are seen with a delayed use of clozapine (Nielsen et al. 2012a, Ucok et al. 2015).”
BackgroundThe Maudsley early onset schizophrenia study: Predictors of psychosocial outcome at 4-year follow-up
Vyas, N. S., Hadjulis, M., Vourdas, A., Byrne, P. J., & Frangou, S. (2007) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-007-0621-4 · Cited by 91 · cited 1×
“Early-onset schizophrenia is associated with worse outcomes compared to adult-onset schizophrenia (Ropcke & Eggers, 2005; Vyas et al. 2007), and a younger age of illness onset has been previously associated with the emergence of T ab le 3.”
Outcomes for schizophrenia patients with clozapine treatment: how good does it get?
Wheeler, A., Humberstone, V., & Robinson, G. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093588 · Cited by 70 · cited 1×
“Early identification of patients who require clozapine has the potential to improve clinical outcomes and minimize the social and functional disability that results from prolonged psychosis (Lewis et al. 2006; Wheeler et al. 2009; Stroup et al. 2016).”
BackgroundMcCutcheon, R. A., Beck, K., Bloomfield, M., Marques, T. R., Rogdaki, M., & Howes, O. D. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115576688 · Cited by 63 · cited 2×
“…and identifying robust associations with the onset of TR. Limitations to our study design include the small population of female patients and the lack of a robust measure of medication adherence, which may have affected the association with meeting the criteria for TR (McCutcheon et al. 2015).”
BackgroundSelf-citationBeck, K., McCutcheon, R. A., Bloomfield, M., Gaughran, F., Marques, T. R., MacCabe, J. H., Selvaraj, S., Taylor, D. M., & Howes, O. D. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12327 · Cited by 62 · cited 1×
“There is some evidence that such an approach is effective in increasing access to clozapine (Beck et al. 2014).”
BackgroundSelf-citationTreatment Response in First-episode Schizophrenia
Schennach, R., Riedel, M. J., Musil, R., & Möller, H. (2012) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2012.10.2.78 · Cited by 57 · cited 1×
“…psychosis (DUP), greater severity of negative symptoms, and a younger age of illness onset have been suggested (Vanelle et al. 1994; Meltzer, 1997; Schennach et al. 2012; Ortiz et al. 2013; Frank et al. 2015; Martin & Mowry, 2016; Wimberley et al. 2016), the predictive value of specific clinical…”
BackgroundClozapine use in childhood and adolescent schizophrenia: A nationwide population-based study
Schneider, C., Papachristou, E., Wimberley, T., Gasse, C., Dima, D., MacCabe, J. H., Mortensen, P. B., & Frangou, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.02.003 · Cited by 54 · cited 1×
“…factors for treatment resistance (TR) have utilized clozapine prescription rates as a proxy measure of TR (Nielsen et al. 2012b; Stroup et al. 2014; Schneider et al. 2015); however, given the under-utilization of clozapine in clinical practice, such studies do not measure all people with TR. *…”
BackgroundSelf-citationLin, C.-C., Wang, Y.-C., Chen, J., Liou, Y., Bai, Y., Lai, I., Chen, T., Chiu, H., & Li, Y. (2008) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2008.02.004 · Cited by 53 · cited 2×
“2016), the predictive value of specific clinical and demographic factors on TR in first-episode schizophrenia has not yet been widely investigated (Lin et al. 2008).”
BackgroundIncreased rare duplication burden genomewide in patients with treatment-resistant schizophrenia
Martin, A. K., & Mowry, B. J. (2015) · Psychological Medicine · doi:10.1017/s0033291715001701 · Cited by 44 · cited 1×
“…a younger age of illness onset have been suggested (Vanelle et al. 1994; Meltzer, 1997; Schennach et al. 2012; Ortiz et al. 2013; Frank et al. 2015; Martin & Mowry, 2016; Wimberley et al. 2016), the predictive value of specific clinical and demographic factors on TR in first-episode schizophrenia…”
BackgroundOrtiz, B. B., Filho, G. M. D. A., Gadelha, A., Medeiros, D., & Bressan, R. A. (2013) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2013-1190 · Cited by 20 · cited 2×
“Although, a few potential risk factors for TR, such as poor premorbid functioning, living in less urban areas, co-morbid personality disorder, longer duration of untreated psychosis (DUP), greater severity of negative symptoms, and a younger age of illness onset have been suggested (Vanelle et al. 1994; Meltzer, 1997;…”
BackgroundNew antipsychotics in schizophrenia: the French experience
Vanelle, J., Olié, J., & Lévy‐Soussan, P. (1994) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1994.tb05834.x · Cited by 17 · cited 1×
“…longer duration of untreated psychosis (DUP), greater severity of negative symptoms, and a younger age of illness onset have been suggested (Vanelle et al. 1994; Meltzer, 1997; Schennach et al. 2012; Ortiz et al. 2013; Frank et al. 2015; Martin & Mowry, 2016; Wimberley et al. 2016), the…”
Background[Treatment refractory schizophrenia].
Vanelle, J. M. (1995) · PubMed · Cited by 5
Research works printed but not linked: 2
- 1994, Schedules for Clinical Assessment in Neuropsychiatry: Version 2: Manual
- 1992, The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines
Cited by
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Self-citationImproving outcomes of first‐episode psychosis: an overview
Fusar‐Poli, P., McGorry, P. D., & Kane, J. M. (2017) · World Psychiatry · doi:10.1002/wps.20446 · Cited by 575
Treatment resistance in psychiatry: state of the art and new directions
Howes, O. D., Thase, M. E., & Pillinger, T. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01200-3 · Cited by 413
Self-citationKaar, S. J., Natesan, S., McCutcheon, R., & Howes, O. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107704 · Cited by 383
Self-citationPotkin, S. G., Kane, J. M., Correll, C. U., Lindenmayer, J.-P., Agid, O., Marder, S. R., Olfson, M., & Howes, O. D. (2020) · npj Schizophrenia · doi:10.1038/s41537-019-0090-z · Cited by 359
Self-citation
Metadata
- Authors
- Lally, J., Ajnakina, O., Di Forti, M., Trotta, A., Demjaha, A., Kolliakou, A., Mondelli, V., Reis Marques, T., Pariante, C., Dazzan, P., Shergil, S. S., Howes, O. D., David, A. S., MacCabe, J. H., Gaughran, F., & Murray, R. M.
- Affiliations
- National Health Service (GB)
- King's College London (GB)
- Corresponding author
- Lally, J.
- ORCID
- Venue
- Psychological Medicine
- Publisher
- Cambridge University Press (CUP)
- Published
- 2016-09-08
- Volume
- 46
- Issue
- 15
- Pages
- 3231-3240
- ISSN
- 0033-2917 (ISSN-L)
- 1469-8978
- OpenAlex
- W2517254183
- Cited by
- 298
- References
- 51
- Citations by year
- 2026: 34 · 2025: 26 · 2024: 31 · 2023: 29 · 2022: 34 · 2021: 36 · 2020: 32 · 2019: 33 · 2018: 29 · 2017: 12 · 2016: 2
- FWCI
- 22.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Psychological Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by-nc-sa)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- Eli Lilly and Company
- Sunovion
- Psychiatry Research Trust
- National Institute for Health and Care Research (CL-2008-17-005, Grant Reference Number RP-PG-0606-1049, NF-SI-0512-10110, 0606-1049, RP-PG-0606-1049, PG-0606-1049)
- Academy of Medical Sciences (AMS-SGCL5-Mondelli)
- King's College London
- Servier
- H. Lundbeck A/S
- Institute of Psychiatry, Psychology and Neuroscience, King’s College London
- Medical Research Council (MR/L003988/1, MR/K004867/1, MR/L011794/1, MR/K013807/1)
- Cilag
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Keywords
- treatment-resistant schizophrenia, first-episode psychosis, schizophrenia spectrum disorders, clozapine, early-onset psychosis, clinical predictors, Black ethnicity, sex differences, antipsychotic treatment resistance, functional disability
- MeSH terms
- Adult, Age Factors, Clozapine, Drug Resistance, Female, Humans, London, Longitudinal Studies, Male, Psychotic Disorders, Risk Factors, Schizophrenia, Schizophrenic Psychology, Sex Factors, Antipsychotic Agents, Odds Ratio, Black People, White People, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.